Summary of Webinar
CYP2D6 is an important pharmacogenetics (PGx) gene as it is involved in the metabolism of ~25% of clinically prescribed drugs. Dr. Cyrine-Eliana Haidar at St Jude Children’s Research Hospital will discuss how to use CYP2D6 genetic information to guide drug dosing and improve patient care, with focus on her many years of experience in managing the medications that are important in oncology care, including ondansetron, tamoxifen, select antidepressants and pain medicines.
Cyrine-Eliana Haidar, PharmD.
Clinical Pharmacogenetics Coordinator, St. Jude Children’s Research Hospital
Dr. Haidar leads the clinical implementation of PGx and is the principal investigator of the institution wide PG4KDS protocol. She is the program coordinator for St. Jude’s ASHP-accredited PGY2 Clinical Pharmacogenomics Residency and an Assistant Professor of Clinical Pharmacy at The University of Tennessee Health Science Center. She is an active member of the Clinical Pharmacogenetics Consortium (CPIC) and has authored 5 CPIC guidelines to date. Dr. Haidar is a founding member of the New Pharmacogenomics Research Network (PGRN).
Please fill in the form to access the webinar.
Webinar Recording: How to use TPMT and NUDT15 PGx
Dr. Manzi at Boston Children’s Hospital and Dr. Scharer at RPRD discussed how to use PGx to reduce Thiopurines-related ADRs in clinical practice.
Order the test
Learn more about the CYP2D6 testing